| Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab H Anwar, C Sachpekidis, J Winkler, A Kopp-Schneider, U Haberkorn, ... European journal of nuclear medicine and molecular imaging 45, 376-383, 2018 | 178 | 2018 |
| Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies K Buder-Bakhaya, K Benesova, C Schulz, H Anwar, ... Cancer Immunology, Immunotherapy 67, 175-182, 2018 | 101 | 2018 |
| The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma C Sachpekidis, H Anwar, J Winkler, A Kopp-Schneider, L Larribere, ... European Journal of Nuclear Medicine and Molecular Imaging 45, 1289-1296, 2018 | 100 | 2018 |
| Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT C Sachpekidis, H Anwar, JK Winkler, A Kopp-Schneider, L Larribere, ... Cancer Immunology, Immunotherapy 67, 1261-1270, 2018 | 24 | 2018 |
| The value of different 18F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients H Anwar, TJ Vogl, MA Abougabal, F Grünwald, P Kleine, S Elrefaie, ... Annals of Nuclear Medicine 32, 687-694, 2018 | 13 | 2018 |
| Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma C Sachpekidis, J Hillengass, H Goldschmidt, H Anwar, U Haberkorn, ... American Journal of Nuclear Medicine and Molecular Imaging 7 (4), 148, 2017 | 8 | 2017 |
| Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: response to mammalian target of rapamycin inhibitor therapy M Schwarzbach, MD Strauss Hellenic Journal of Nuclear Medicine 20 (2), 169-171, 2017 | 6 | 2017 |
| Influence of metabolic tumor burden on reference tissues’ standardized uptake values in 18F-FDG PET/CT sequential imaging A Badawy, MM Maamoun, AA Kandeel, H Anwar Egyptian Journal of Radiology and Nuclear Medicine 54 (1), 195, 2023 | 1 | 2023 |
| Absolute number of new lesions in 18F-FDG PET/CT is more predictive of clinical outcome than SUV changes in metastatic melanoma patients receiving ipilimumab H Anwar, C Sachpekidis, J Winkler, A Kopp-Schneider, U Haberkorn, ... EANM'17, 2017 | 1 | 2017 |
| Influence of Metabolic Tumor Burden on reference tissues’ Standardized Uptake Values in 18F-FDG PET/CT sequential imaging of lymphoma patients A Kandeel, M Maamoun, A Badawy, H Anwar Journal of Nuclear Medicine 64 (supplement 1), P1045-P1045, 2023 | | 2023 |
| Causes and Clinical Impact of Loss to Follow-Up in Patients with Differentiated Thyroid Cancer in Nuclear Medicine Department, single institution experience. A Kandeel, A Abdou, E Eltahlawy, H Anwar Journal of Nuclear Medicine 64 (supplement 1), P1028-P1028, 2023 | | 2023 |
| Delineating Metabolic Tumor Volume In NSCLC: Which Thresholding Method Should Be Used? H Anwar, T Vogl, M Abougabal, F Grünwald, P Kleine, S Elrefaie, ... EANM'19, 2019 | | 2019 |
| Die prognostische Rolle von F-18-FDG PET/CT Untersuchungen für die Evaluation der Ipilimumab Therapie bei Patienten mit metastasiertem Melanom H Anwar | | 2019 |
| Prognostic Role of F-18-FDG PET, CT Studies for Treatment Evaluation of Ipilimumab in Metastatic Melanoma Patients H Anwar Ruprecht-Karls-Universität zu Heidelberg, 2018 | | 2018 |
| Value of EORTC criteria in treatment monitoring of melanoma patients receiving ipilimumab H Anwar, C Sachpekidis, J Winkler, J Hassel, U Haberkorn, ... Journal of Nuclear Medicine 58 (supplement 1), 1089-1089, 2017 | | 2017 |
| Prognostic value of post-treatment 18F-FDG PET/CT studies in melanoma patients receiving ipilimumab H Anwar, C Sachpekidis, J Winkler, J Hassel, U Haberkorn, ... Journal of Nuclear Medicine 58 (supplement 1), 1088-1088, 2017 | | 2017 |
| Characterization of Arthralgia under PD-1 Inhibitor Therapy K Buder-Bakhaya, K Benesova, H Anwar, T Weber, ... JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 15, 87-88, 2017 | | 2017 |
